Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on March 29, 2022, covering events occurring on March 28, 2022. The filing details the execution of Transition Agreements with two senior executives, Dr. Michael G. Kauffman (Senior Clinical Advisor) and Dr. Sharon Shacham (Chief Scientific Officer), outlining their separation from employment and associated compensation arrangements.
Key Financial Metrics
This filing does not report consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and severance terms.
- Dr. Kauffman Base Salary: $388,125 annualized.
- Dr. Kauffman Severance Rate: $646,875 per annum for 18 months.
- Dr. Shacham Base Salary: $519,901 annualized.
- Dr. Shacham Severance Rate: $519,901 per annum (duration not explicitly quantified in text, referenced as "Severance Period").
- Dr. Shacham New Equity Grant: 90,000 stock options (exercise price $\ge$ $10.33) and 60,000 RSUs.
Material Changes
The primary material change is the departure of two key scientific leaders:
- Dr. Michael G. Kauffman: Separation effective May 31, 2022. He waived his right to be nominated to the Board of Directors.
- Dr. Sharon Shacham: Separation effective May 31, 2022. She ceased serving as a Board observer immediately and waived related rights. She will transition to a consulting role until May 31, 2023.
Outlook, Risks, and Unusual Items
Compensation Contingencies: Severance benefits for both executives are contingent upon the timely execution and non-revocation of a separation and release of claims agreement. Benefits are forfeited if the executives resign without "Good Reason" or are terminated for "Cause" prior to the Separation Date.
Equity Vesting: Both executives are entitled to accelerated vesting of certain unvested equity awards. Dr. Shacham's new equity awards vest over a four-year period, with 25% vesting annually for RSUs and monthly thereafter for options after the first year.
Consulting Arrangement: Dr. Shacham will provide advisory services for up to five hours per week under a new consulting agreement, with fees paid hourly.
Investor Verification Checklist
- Verify the total cash outflow for severance by calculating the 18-month period for Dr. Kauffman and confirming the specific duration of the "Severance Period" for Dr. Shacham in the full agreement text.
- Confirm the exact exercise price of Dr. Shacham's new stock options, which is the greater of $10.33 or the closing price on the grant date.
- Review the full text of Exhibits 10.1 and 10.2 to understand the specific definitions of "Good Reason" and "Cause" which impact severance eligibility.
- Assess the impact of losing two senior scientific advisors on the company's clinical trial timelines and pipeline development.